Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

30.20 +0.16 (+0.55%)
Streaming Delayed Price Updated: 9:57 AM EDT, Mar 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces R&D leadership evolution
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
From Immunocore Holdings plc
Via GlobeNewswire
News headline image
Immunocore to present at the 2024 Cantor Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.